Natera, Inc. Common Stock NTRA

Natera, Inc. es una empresa de diagnóstico que se enfoca en el desarrollo y comercialización de servicios de pruebas moleculares, aplicando su tecnología en los campos de la salud de la mujer, oncología y salud de órganos. Su tecnología de ácido desoxirribonucleico (ADN) libre de células (cfDNA) combina sus ensayos moleculares, que miden de manera confiable muchas regiones informativas en todo el genoma a partir de muestras tan pequeñas como una sola célula. La oferta de productos de la empresa incluye la Prueba Prenatal No Invasiva Panorama (NIPT), Vistara, Prueba de Portador Horizon (HCS), Genética Preimplantacional Spectrum, Prueba de Aborto Espontáneo Anora (Anora) y Prospera. La empresa también ofrece Constellation, una plataforma de software basada en la nube que permite a los clientes de laboratorio acceder a través de la nube a los algoritmos y bioinformática de la empresa para validar y lanzar pruebas basadas en la tecnología de la empresa. Su NIPT detecta anomalías cromosómicas de un feto, así como en embarazos gemelares, generalmente con una extracción de sangre de la madre.

• Zacks Investment Research 23 sept

  Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx

  Natera announced that its Signatera test received regulatory approval from Japan's PMDA as a companion diagnostic for muscle-invasive bladder cancer (MIBC), supporting Signatera-guided adjuvant atezolizumab treatment decisions. The approval, supported by IMvigor011 Phase III trial data, marks the company's second PMDA authorization in three months. Commercial launch in Japan is planned for H1 2027. The stock gained 5.5% following the announcement.

  

• The Motley Fool 14 sept

  This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?

  Stanley Druckenmiller's Duquesne family office has maintained Natera as its largest holding for 8 consecutive quarters. The medical diagnostics company uses liquid biopsy technology for cancer detection and other applications, showing strong growth with 57% year-over-year increase in oncology tests and 38% revenue growth. Despite persistent losses, the company has strong cash reserves and is projected to approach profitability by 2027. However, the stock has surged 87% in the past year with a lofty price-to-sales ratio of 17.

  

• The Motley Fool 8 sept

  Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)

  Billionaire investor Stanley Druckenmiller holds positions in Amazon and Alphabet for AI infrastructure exposure, but his largest U.S. stock holding is Natera, a genetic diagnostics company that has returned approximately 10x since his initial investment in Q3 2022. Druckenmiller sold his Nvidia position in early 2024 due to valuation concerns and now holds Taiwan Semiconductor Manufacturing as his AI semiconductor bet instead.

  

• The Motley Fool 8 ago

  Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.

  Billionaire investor Stanley Druckenmiller has dramatically reduced his exposure to megacap tech stocks, holding only Amazon as a minor position (0.32%) among the Magnificent Seven and completely exiting Alphabet. Instead, he's concentrating his $3 billion portfolio in biotech (Natera at 21%), semiconductors (Taiwan Semiconductor at 5.7%), and emerging markets, while adding positions in semiconductor suppliers like Broadcom, Micron, and STMicroelectronics.